Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Philippe Armand; Arnon Nagler; Edie Weller; Steven M. Devine; David Avigan; Yi‐Bin Chen; Mark Kaminski; H. Kent Holland; Jane N. Winter; James R. Mason; Joseph W. Fay; David A. Rizzieri; Chitra Hosing; Edward D. Ball; Joseph P. Uberti; Hillard M. Lazarus; Markus Y. Mapara; Stephanie A. Gregory; John M. Timmerman; David Andorsky; Reuven Or; Edmund K. Waller; Rinat Rotem‐Yehudar; Leo I. Gordon

doi:10.1200/jco.2012.48.3685

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

This is the first demonstration of clinical activity of PD-1 blockade in DLBCL. Given these results, PD-1 blockade after AHSCT using pidilizumab may represent a promising therapeutic strategy in this disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Armand et al. (2013) studied this question.

synapsesocial.com/papers/69d900b749e640f9cad18012 https://doi.org/10.1200/jco.2012.48.3685

View Full Paper

Ask AI

Bookmark

Share

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading